

Modeling collaterally sensitive drug cycles: shaping heterogeneity to allow adaptive therapy

Nara Yoon (*presenter*)^{1,2}, Robert Vander Velde^{3,4},
Nikhil Krishnan^{2,5}, Andriy Marusyk³, Jake Scott^{2,5}

¹*Adelphi University, Garden city, NY* ;

*THOR*², Cleveland Clinic, Cleveland, OH ;

³*Moffit Cancer Center, Tampa, FL* ;

⁴*Univ. of South Florida, Tampa, FL* ;


⁵*Sch. of Medicine, CWRU, Cleveland, OH* ;

CATMO2020

December 10, 2020, 11 am – 11:20 am


1. Background

Drug resistance




1. Background

Drug resistance




Dynamics of tumor heterogeneity




1. Background


Drug resistance



Dynamics of tumor heterogeneity




Collateral sensitivity



2. Model for 2 drugs

Fundamental modeling structure of a heterogeneous cell population



- Dynamic variables:
 - C_S : sensitive cell population
 - C_R : resistant cell population
 - $C_S + C_R$: total tumor size, **disease burden**
- Parameters:
 - $s < 0, r > 0$: net proliferation rates for C_S and C_R (birth *minus* death, $s = b_s - d_s, r = b_r - d_r$)
 - $g > 0$: rate or resistance acquisition due to therapy

Deterministic ODE system depends on $\{s, r, g | C_S^0, C_R^0\}$

$$\begin{pmatrix} \dot{C}_S \\ \dot{C}_R \end{pmatrix} = \begin{pmatrix} s - g & 0 \\ g & r \end{pmatrix} \begin{pmatrix} C_S \\ C_R \end{pmatrix}, \quad \begin{pmatrix} C_S \\ C_R \end{pmatrix}_{t=0} = \begin{pmatrix} C_S^0 \\ C_R^0 \end{pmatrix}$$


Solution

$$C_S(t) = C_S^0 e^{-(g-s)t}$$

$$C_R(t) = A e^{-(g-s)t} + B e^{r t}$$

$$C_S(t) + C_R(t) = A' e^{-(g-s)t} + B e^{r t}$$


positive




2. Model for 2 drugs

Modeling of collateral sensitive network


With Drug A



With Drug B



- Dynamic variables:
 - R_A : resistant to *Drug A* sensitive to *Drug B*
 - R_B : resistant to *Drug B* sensitive to *Drug A*
 - $R_A + R_B$: total tumor size, **disease burden**
- Parameters:
 - $\{s_A = b_A^s - d_A^s, r_A = b_A^r - d_A^r, g_A\}$ for *Drug A*
 - $\{s_B = b_B^s - d_B^s, r_B = b_B^r - d_B^r, g_B\}$ for *Drug B*
- Initial population makeup: $ApB_0 = R_A^0/R_B^0$
- Drug Switches
 - (e.g.) (A-drug, 1 week) \rightarrow (B-drug, 1.5 week) \rightarrow ...



2. Model for 2 drugs


Analysis: strategic drug-switch timing

1. T_{max} : clinical intuition

The longest time period with *Drug A* lasting effective.

$$T_{max}(\{s_A, r_A, g_A\}, ApB_0) = \frac{\log \left[\frac{(g_A - s_A)(r_A - s_A)}{r_A(g_A(1 + ApB_0) + ApB_0(r_A - s_A))} \right]}{g_A + r_A - s_A},$$

which exists if and only if (iff) $ApB_0 < |s_A/r_A|$,
where $ApB_0 = R_A(0)/R_B(0)$.



(Blue) *Drug A* alone

(Red) *Drug B* alone

(Used parameters)

$$s_A = s_B = -0.09, r_A = r_B = 0.008,$$

$$g_A = g_B = 0.001, \{R_A^0, R_B^0\} = \{0.1, 0.9\}$$

2. Model for 2 drugs

Analysis: strategic drug-switch timing

1. T_{max} : clinical intuition

The longest time period with *Drug A* lasting effective.

$$T_{max}(\{s_A, r_A, g_A\}, ApB_0)$$

$$= \frac{\log \left[\frac{(g_A - s_A)(r_A - s_A)}{r_A(g_A(1 + ApB_0) + ApB_0(r_A - s_A))} \right]}{g_A + r_A - s_A},$$

which exists if and only if (iff) $ApB_0 < |s_A/r_A|$,
where $ApB_0 = R_A(0)/R_B(0)$.

2. T_{min} suggests improvement


Population decreases even faster by switch from *Drug A* to *Drug B* at or after:

$$T_{min}(\{s_A, r_A, g_A\}, \{s_B, r_B\}, ApB_0)$$

$$= \frac{\log \left[\frac{(r_A - s_A)(r_B - s_A) + g_A(r_A + r_B - s_A - s_B)}{(g_A + ApB_0(g_A + r_A - s_A))(r_A - s_B)} \right]}{g_A + r_A - s_A},$$

which exists iff $ApB_0 < |(r_B - s_A)/(r_A - s_B)|$

Condition: $T_{min} < T_{max}$ iff $r_A r_B < s_A s_B$



(Blue) Drug A alone

(Red) Drug B alone

(Dashed magenta) arbitrary switch

(Used parameters)

$s_A = s_B = -0.09$, $r_A = r_B = 0.008$,

$g_A = g_B = 0.001$, $\{R_A^0, R_B^0\} = \{0.1, 0.9\}$

2. Model for 2 drugs

Analysis: strategic drug-switch timing

1. T_{max} : clinical intuition

The longest time period with *Drug A* lasting effective.

$$T_{max}(\{s_A, r_A, g_A\}, ApB_0) = \frac{\log \left[\frac{(g_A - s_A)(r_A - s_A)}{r_A(g_A(1 + ApB_0) + ApB_0(r_A - s_A))} \right]}{g_A + r_A - s_A},$$

which exists if and only if (iff) $ApB_0 < |s_A/r_A|$,
where $ApB_0 = R_A(0)/R_B(0)$.


2. T_{min} suggests improvement

Population decreases even faster by switch from *Drug A* to *Drug B* at or after:

$$T_{min}(\{s_A, r_A, g_A\}, \{s_B, r_B\}, ApB_0) = \frac{\log \left[\frac{(r_A - s_A)(r_B - s_A) + g_A(r_A + r_B - s_A - s_B)}{(g_A + ApB_0(g_A + r_A - s_A))(r_A - s_B)} \right]}{g_A + r_A - s_A},$$

which exists iff $ApB_0 < |(r_B - s_A)/(r_A - s_B)|$

Condition: $T_{min} < T_{max}$ iff $r_A r_B < s_A s_B$



(Blue) *Drug A* alone

(Red) *Drug B* alone

(Dashed magenta) arbitrary switch

(Black) instantaneous switch

(Used parameters)

$s_A = s_B = -0.09$, $r_A = r_B = 0.008$,

$g_A = g_B = 0.001$, $\{R_A^0, R_B^0\} = \{0.1, 0.9\}$

2. Model for 2 drugs

Analysis: population makeup at T_{\min} and T_{\max}

- Population makeup:


$$ApB(t) := R_A(t)/R_B(t)$$

- $ApB(T_{\min}^A) = ApB(T_{\min}^B) = \frac{r_B - s_A}{r_A - s_B} := ApB^*$,
- $ApB(T_{\max}^A) = \frac{-s_A}{r_A}$, $ApB(T_{\max}^B) = \frac{r_B}{-s_B}$

- Drug effect at ApB :

$$\left. \frac{d}{dt} P(t) \right|_{t=0}^{\{s_i, r_i, g_i\}, ApB_0}, \quad P(t) = R_A(t) + R_B(t), \quad P(0) = 1 \text{ (fixed)}$$

when $r_A r_B < s_A s_B$




2. Model for 2 drugs

Optimal control consists of **two stages** of therapy



(*Stage 1; shaping*) until T_{min} , “better” drug alone

(*Stage 2; adaptive therapy*) combination of the two drugs switched in turn with a definite ratio in duration, k , i.e., *Drug A* for t days and *Drug B* for k times t days.

$$k^{(i)}(\{s_A, r_A, g_A\}, \{s_B, r_B, g_B\}, \Delta t)$$



$$\lim_{\Delta t \rightarrow 0} k = \lim_{\Delta t \rightarrow 0} k' = \frac{((r_A - s_A)(r_B - s_A) + g_A(r_A + r_B - s_A - s_B))(r_A - s_B)}{((r_A - s_B)(r_B - s_B) + g_B(r_A + r_B - s_A - s_B))(r_B - s_A)} := k^*$$



(Used parameters)

$$\{s_A, s_B\} = -0.09\{2, 1\}, \quad \{r_A, r_B\} = 0.008\{1, 2\}, \\ \{g_A, g_B\} = 0.001\{0.75, 1.25\}, \quad \{R_A^0, R_B^0\} = \{0.1, 0.9\}$$

2. Model for 2 drugs

Simple analytic description of Stage 2 of the optimal control

- Differential system on Stage 2:**

Drug A for $(k^* \Delta t)$ -long period $\begin{pmatrix} \dot{R}_A \\ \dot{R}_B \end{pmatrix} = \begin{pmatrix} r_B & g_B \\ 0 & s_B - g_B \end{pmatrix} \begin{pmatrix} R_A \\ R_B \end{pmatrix} := \mathbb{D}_A \begin{pmatrix} R_A \\ R_B \end{pmatrix},$

Drug B for Δt -long period $\begin{pmatrix} \dot{R}_A \\ \dot{R}_B \end{pmatrix} = \begin{pmatrix} s_A - g_A & 0 \\ g_A & r_A \end{pmatrix} \begin{pmatrix} R_A \\ R_B \end{pmatrix} := \mathbb{D}_B \begin{pmatrix} R_A \\ R_B \end{pmatrix}$

Drug A for $(k^* \Delta t)$ -long period

...

as $\Delta t \rightarrow 0$

$$\begin{pmatrix} \dot{R}_A \\ \dot{R}_B \end{pmatrix} = \left[\frac{k^*}{1+k^*} \mathbb{D}_A + \frac{1}{1+k^*} \mathbb{D}_B \right] \begin{pmatrix} R_A \\ R_B \end{pmatrix}$$

- Stage 2 starts at T_{min} :**

$$ApB(T_{min}) = ApB^*$$

- Populations on stage 2**

$$P(t + T_{min}) = P(T_{min}) \text{Exp}(\lambda t)$$

$$\text{for } P \in \{R_A, R_B, R_A + R_B\}$$


where
$$\lambda = - \frac{r_A r_B - s_A s_B}{r_A + r_B + s_A + s_B}$$

Details of the proof is shown in
[Yoon et al., bulletin of
mathematical biology, 2018]

3. Model for n drugs

Collateral Sensitivity cycle of length N :

$\text{Drug 1} \rightarrow \text{Drug 2} \rightarrow \dots \rightarrow \text{Drug } N \rightarrow \text{Drug 1} \rightarrow \dots$




N dynamic variables:

- R_i : resistant to *Drug i*
- R_{i-1} (or R_N): sensitive to *Drug i* (or *Drug 1*)
- R_j : neutral to *Drug i* ($j \notin \{i-1, i\}$)

$N \times 5$ parameters:

- Proliferation rates: $\{p_r^i > 0, p_s^i < 0, p_0^i\}$ for *Drug i*
- Transition rates: $\{g_s^i, g_0^i\}$ for *Drug i*



3. Model for n drugs

Dynamics of cell populations under *Drug i*: $\frac{dv}{dt} = \mathcal{M}(i) v$ where $v = (R_1, \dots, R_N)^T$

(i-1)-th column
↓

$$\mathcal{M}(i) = \begin{pmatrix} \lambda_0^i & 0 & \dots & 0 & \overline{g_s^i} & 0 & \dots & \dots & \dots & 0 \\ 0 & \ddots & \ddots & \vdots & \vdots & \vdots & \dots & \dots & \dots & \vdots \\ \vdots & \ddots & \ddots & 0 & \vdots & \vdots & \dots & \dots & \dots & \vdots \\ \vdots & & \ddots & \lambda_0^i & \overline{g_s^i} & \vdots & \dots & \dots & \dots & \vdots \\ 0 & \dots & \dots & 0 & \lambda_r^i & 0 & \dots & \dots & \dots & 0 \\ g_0^i & \dots & \dots & g_0^i & 0 & \lambda_r^i & g_s^i & \dots & \dots & g_s^i \\ 0 & \dots & \dots & 0 & \overline{g_s^i} & 0 & \lambda_0^i & 0 & \dots & 0 \\ \vdots & & & \vdots & \vdots & \vdots & \ddots & \ddots & \ddots & \vdots \\ \vdots & & & \vdots & \vdots & \vdots & & \ddots & \ddots & 0 \\ 0 & \dots & \dots & 0 & \overline{g_s^i} & 0 & \dots & \dots & 0 & \lambda_0^i \end{pmatrix}$$

← (i-1)-th row
← i-th row

With

- $(\lambda_r^i, \lambda_s^i, \lambda_0^i) = (p_r^i, p_s^i - g_s^i, p_0^i - g_0^i)$
- $\overline{g_s^i} = \frac{g_s^i}{N-2}$

3. Model for n drugs

Availability of **analytic** derivations

	2- drugs	n-drugs
Drug switch time (T_{min})	Yes	No
Population makeup with same drug effect (ApB^* or v^*)	Yes	Yes
Relative drug period (k^*)	Yes	No
Metaphor problem	$a^x = b$ (analytically solvable)	$a^x + b^x = c$ (analytically proved to have a solution; numerically solvable)



Total cell population with optimal therapy

$$\frac{dv}{dt} = \mathcal{M} \left(\underset{1 \leq i \leq N}{\operatorname{argmin}} ef_i \right) v$$

where $ef_i(t) = \mathcal{P}^i \cdot v(t)$

Discretely solvable by finding the best drug at every discrete time point and solve $v' = \mathcal{M}(j) v$ until the next point.

3. Model for n drugs



↑ Example of optimal therapy simulation compared to a non-optimal therapy

← Diagram to run optimal therapy over a discrete timeline

3. Model for n drugs

Example with 4 of **symmetric** drugs

$$\{p_r, p_s, p_0\} = \{0.2, -0.7, 0.1\}, \{g_s, g_0\} = \{0.1, 0.05\},$$

$$\{R_1^0, R_2^0, R_3^0, R_4^0\} = \{0.45, 0.3, 0.05, 0.2\}$$

Example 4 of **asymmetric** drugs

$$\{p_r^1 p_s^1, p_0^1\} = \{0.5, -0.7, 0.0\}, \{g_s^1, g_0^1\} = \{0.01, 0.005\},$$

$$\{p_r^2 p_s^2, p_0^2\} = \{0.1, -0.7, 0.0\}, \{g_s^2, g_0^2\} = \{0.01, 0.01\},$$

$$\{p_r^3 p_s^3, p_0^3\} = \{0.2, -0.3, 0.0\}, \{g_s^3, g_0^3\} = \{0.05, 0.05\},$$



$$\{p_r^4 p_s^4, p_0^4\} = \{0.1, -0.2, 0.0\}, \{g_s^4, g_0^4\} = \{0.001, 0.0005\},$$

$$\{R_1^0, R_2^0, R_3^0, R_4^0\} = \{0.05, 0.15, 0.2, 0.6\}$$

3. Model for n drugs


An example with symmetric drugs

$$\{p_r, p_s, p_0\} = \{0.2, -0.7, 0.1\}, \{g_s, g_0\} = \{0.1, 0.05\}, \{R_1^0, R_2^0, R_3^0, R_4^0\} = \{0.45, 0.3, 0.05, 0.2\}$$



$$v^* = \lambda(1, \dots, 1)^T$$



$$\text{Decay rate: } \frac{p_r + p_s + (N-2)p_0}{N}$$



3. Model for n drugs

An example with asymmetric drugs

$$\begin{aligned} \{p_r^1 p_s^1, p_0^1\} &= \{0.5, -0.7, 0.0\}, \{g_s^1, g_0^1\} = \{0.01, 0.005\}, \{p_r^2 p_s^2, p_0^2\} = \{0.1, -0.7, 0.0\}, \\ \{g_s^2, g_0^2\} &= \{0.01, 0.01\}, \{p_r^3 p_s^3, p_0^3\} = \{0.2, -0.3, 0.0\}, \{g_s^3, g_0^3\} = \{0.05, 0.05\}, \\ \{p_r^4 p_s^4, p_0^4\} &= \{0.1, -0.2, 0.0\}, \{g_s^4, g_0^4\} = \{0.001, 0.0005\}, \{R_1^0, R_2^0, R_3^0, R_4^0\} = \\ &= \{0.05, 0.15, 0.2, 0.6\} \end{aligned}$$





$$v^* = \lambda \begin{pmatrix} (\mathcal{P}^1)^T \\ \vdots \\ (\mathcal{P}^N)^T \end{pmatrix}^{-1} \begin{pmatrix} 1 \\ \vdots \\ 1 \end{pmatrix}$$

Decay rate:??

3. Model for n drugs

An example with asymmetric drugs

$$\begin{aligned} \{p_r^1 p_s^1, p_0^1\} &= \{0.5, -0.7, 0.0\}, \{g_s^1, g_0^1\} = \{0.01, 0.005\}, \{p_r^2 p_s^2, p_0^2\} = \{0.1, -0.7, 0.0\}, \\ \{g_s^2, g_0^2\} &= \{0.01, 0.01\}, \{p_r^3 p_s^3, p_0^3\} = \{0.2, -0.3, 0.0\}, \{g_s^3, g_0^3\} = \{0.05, 0.05\}, \\ \{p_r^4 p_s^4, p_0^4\} &= \{0.1, -0.2, 0.0\}, \{g_s^4, g_0^4\} = \{0.001, 0.0005\}, \{R_1^0, R_2^0, R_3^0, R_4^0\} = \\ &= \{0.05, 0.15, 0.2, 0.6\} \end{aligned}$$



Within each stage, since the entropy graph is flat on each stage, drugs are periodically switching with relative period from the bar chart.


3. Model for n drugs

Instantaneous drug switch is supposed to be consistent with the **linear combination** of the dynamics with corresponding intensities (as numerically tested).




Drug 1 for $(f_1 \Delta t)$ -long period,
 Drug 2 for $(f_2 \Delta t)$ -long period
 ...
 Drug N for $(f_N \Delta t)$ -long period
 Drug 1 for $(f_1 \Delta t)$ -long period
 ...

$$\mathbf{v} = \left(\sum_{i=1}^N f_i \mathcal{M}(i) \right) \mathbf{v}$$

Symmetric drugs



Asymmetric drugs



4. Optimal regimen without parameters

1. Subpopulations are know (e.g., cell free DNA):

Three equations from the explicit solutions of the ODE system, for $R_i, R_{i-1}, \sum_{j \notin \{i-1, i\}} R_j$

Calibration of **5 parameters**

Hypotheses with mutation per proliferation
 $g_0^i = \alpha_0 p_0^i$ and $g_s^i = \alpha_s p_s^i$


2. Only total population is know (e.g., Prostate Specific Atigen):



Computational algorithm??


4. Optimal regimen without parameters

Algorithm to prescribe optimal regimen without parameters




4. Optimal regimen without parameters

Algorithm to prescribe optimal regimen without parameters




Good consistency with $\epsilon = 0.01$




Errors of the algorithm over a range of ϵ

Conclusions

- Population structure




- Population makeup with balanced drug effects



- Numerically figured out optimal control




$$\frac{dv}{dt} = \mathcal{M} \left(\underset{1 \leq i \leq N}{\operatorname{argmin}} ef_i \right) v$$

- Optimal prescription without drug parameters known



Future work

- Considerations on the third type of cells (Areeba Khalid, Adelphi)



- Find combinations of collaterally sensitive factors from RNA (miRNA), DNA, network data
- Interdisciplinary implementation of the optimal therapy in the automatic cell culturing device, Mobidostat.
- Expansion of the model considering spatial distribution of microenvironment.

Thank you all!!



Theory Division

Math & CS at Adelphi



Thank you! Questions?